BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21887684)

  • 1. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    Cancer; 2012 May; 118(9):2532-40. PubMed ID: 21887684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    J Surg Oncol; 2012 Jul; 106(1):24-30. PubMed ID: 22252429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
    Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
    JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    Clin Cancer Res; 2011 May; 17(10):3293-303. PubMed ID: 21307149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular staging of node negative patients with colorectal cancer.
    Hyslop T; Waldman SA
    J Cancer; 2013; 4(3):193-9. PubMed ID: 23459453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular staging estimates occult tumor burden in colorectal cancer.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Adv Clin Chem; 2010; 52():19-39. PubMed ID: 21275338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
    Cagir B; Gelmann A; Park J; Fava T; Tankelevitch A; Bittner EW; Weaver EJ; Palazzo JP; Weinberg D; Fry RD; Waldman SA
    Ann Intern Med; 1999 Dec; 131(11):805-12. PubMed ID: 10610624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanylyl cyclase C as a biomarker in colorectal cancer.
    Hyslop T; Waldman SA
    Biomark Med; 2013 Feb; 7(1):159-67. PubMed ID: 23387497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study.
    Chen G; McIver CM; Texler M; Lloyd JM; Rieger N; Hewett PJ; Sen Wan D; Hardingham JE
    Dis Colon Rectum; 2004 May; 47(5):679-86. PubMed ID: 15037935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previstage GCC test for staging patients with colorectal cancer.
    Mejia A; Waldmana SA
    Expert Rev Mol Diagn; 2008 Sep; 8(5):571-8. PubMed ID: 18785805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients.
    Bustin SA; Siddiqi S; Ahmed S; Hands R; Dorudi S
    Int J Cancer; 2004 Jan; 108(3):412-7. PubMed ID: 14648708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors of lymph node-negative metastasis gastric cancer].
    Sun D; Xu H; Huang J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):190-194. PubMed ID: 28226354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas: an immunohistochemical study.
    Broll R; Schauer V; Schimmelpenning H; Strik M; Woltmann A; Best R; Bruch HP; Duchrow M
    Dis Colon Rectum; 1997 Dec; 40(12):1465-71. PubMed ID: 9407986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
    Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence.
    Sanchez-Cespedes M; Esteller M; Hibi K; Cope FO; Westra WH; Piantadosi S; Herman JG; Jen J; Sidransky D
    Clin Cancer Res; 1999 Sep; 5(9):2450-4. PubMed ID: 10499618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
    Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
    Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of isolated tumour cells in regional lymph nodes from pN0 colorectal cancer.
    Mescoli C; Rugge M; Pucciarelli S; Russo VM; Pennelli G; Guido M; Nitti D
    J Clin Pathol; 2006 Aug; 59(8):870-4. PubMed ID: 16603645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer.
    Mescoli C; Albertoni L; Pucciarelli S; Giacomelli L; Russo VM; Fassan M; Nitti D; Rugge M
    J Clin Oncol; 2012 Mar; 30(9):965-71. PubMed ID: 22355061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients.
    Rosenberg R; Hoos A; Mueller J; Baier P; Stricker D; Werner M; Nekarda H; Siewert JR
    J Clin Oncol; 2002 Feb; 20(4):1049-55. PubMed ID: 11844829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.